Latest Conference Articles

Stay up to date on the latest oncology and nursing conferences.

Daly Discusses Biomarkers and Emerging Targeted Therapies for Cancer Care

Daly Discusses Biomarkers and Emerging Targeted Therapies for Cancer Care

September 20th 2022, 6:00pm

Kristin Daly, MSN, ANP-BC, AOCNP, discusses the clinical significance of tumor variants and how they are changing the direction of cancer care.

TIL Therapy Outperforms Ipilimumab in Extending Progression-Free Survival in Unresectable Melanoma

TIL Therapy Outperforms Ipilimumab in Extending Progression-Free Survival in Unresectable Melanoma

September 20th 2022, 2:00pm

At a median follow-up of 33.0 months, the median progression-free survival with tumor-infiltrating lymphocyte therapy was 7.2 months vs 3.1 months with ipilimumab.

Real-World HRQOL Findings Support Nivolumab for Previously Treated mRCC

Real-World HRQOL Findings Support Nivolumab for Previously Treated mRCC

September 19th 2022, 6:00pm

Results of retrospective analysis of previously treated patients with metastatic renal cell carcinoma who received nivolumab in the second- and third-line showed that health-related quality of life was maintained in the real-world setting

Pembrolizumab Plus Bevacizumab and Cyclophosphamide Shows Promising Efficacy, Tolerability in Recurrent Ovarian Cancer

Pembrolizumab Plus Bevacizumab and Cyclophosphamide Shows Promising Efficacy, Tolerability in Recurrent Ovarian Cancer

September 19th 2022, 2:00pm

Real-world data from a retrospective study showed that pembrolizumab combined with the anti-VEGF agent bevacizumab plus oral metronomic cyclophosphamide displayed minimal toxicity in a significant number of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Pembrolizumab Potentially Most Effective Before Surgery in High-Risk Melanoma

Pembrolizumab Potentially Most Effective Before Surgery in High-Risk Melanoma

September 18th 2022, 2:00pm

The rate of event-free survival associated with pembrolizumab was significantly higher among patients with high-risk melanoma about to undergo surgery than among those who received immunotherapy following surgery.

Trastuzumab Deruxtecan Continues to Elicit Encouraging Responses in Patients With Metastatic Gastric/GEJ Cancer

Trastuzumab Deruxtecan Continues to Elicit Encouraging Responses in Patients With Metastatic Gastric/GEJ Cancer

September 17th 2022, 2:00pm

After 10 months of follow-up, the confirmed objective response rate among patients with metastatic gastric cancer or gastroesophageal junction adenocarcinoma who received trastuzumab deruxtecan was 41.8%.

Oncology Nurses: What Cannabinoid Is Your Patient Taking?

Oncology Nurses: What Cannabinoid Is Your Patient Taking?

September 16th 2022, 6:00pm

Karen Hande, PhD(c), DNP, ANP-BC, CNE, FAANP, ANEF, explains the difference between some of the popular cannabinoid products that patients with cancer may be taking.

Real-World Data Show TRAEs Associated With Improved Survival With Atezolizumab plus Bevacizumab in HCC

Real-World Data Show TRAEs Associated With Improved Survival With Atezolizumab plus Bevacizumab in HCC

September 16th 2022, 2:27pm

A multicentre, retrospective study showed that treatment-related adverse effects associated with atezolizumab plus bevacizumab were prognostic of improvements in survival outcomes in patients with hepatocellular carcinoma.

Dose-Optimized Regorafenib Provides Comparable, Safe Option for mCRC

Dose-Optimized Regorafenib Provides Comparable, Safe Option for mCRC

September 15th 2022, 2:00pm

Patients with relapsed or refractory metastatic colorectal cancer who received dose-optimized regorafenib achieved superior survival outcomes than those who received best supportive care, fruquintinib, standard-dose regorafenib, and trifluridine/tipiracil.

Neoadjuvant Nivolumab/Ipilimumab Yields 95% Major Pathological Response Rate in dMMR Colon Cancer

Neoadjuvant Nivolumab/Ipilimumab Yields 95% Major Pathological Response Rate in dMMR Colon Cancer

September 13th 2022, 6:00pm

Neoadjuvant immunotherapy starkly outperformed neoadjuvant chemotherapy in eliciting major pathological responses among patients with mismatch repair–deficient colon cancer, according to investigators.